← Back to Clinical Trials
Recruiting NCT05607654

NCT05607654 The Mechanisms of Underlying Accelerated Repetitive Transcranial Magnetic Stimulation for Treatment-resistant Depression

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT05607654
Status Recruiting
Phase
Sponsor First Affiliated Hospital of Zhejiang University
Condition Treatment-resistant Depression
Study Type INTERVENTIONAL
Enrollment 60 participants
Start Date 2023-01-01
Primary Completion 2024-12-31

Eligibility & Interventions

Sex All sexes
Min Age 18 Years
Max Age 45 Years
Study Type INTERVENTIONAL
Interventions
active iTBSsham rTMS

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 60 participants in total. It began in 2023-01-01 with a primary completion date of 2024-12-31.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

In this project, the investigators evaluate an accelerated schedule of repetitive transcranial magnetic stimulation for treatment-resistant depression. The investigators focuse on participants' brain activity and blood markers (Reelin, Apoer2, NMDAR, BDNF, exosomes and so on) to deepen the understanding of the mechanism of accelerated rTMS for treatment-resistant depression.

Eligibility Criteria

Inclusion Criteria: 1. The current episode met the DSM-5 diagnostic criteria for major depression in patients with first-episode or relapsed unmedicated depression without psychotic symptoms. 2. 24-item Hamilton Depression Scale (HAMD-24) ≥ 20. 3. Age 18-45 years, regardless of gender. 4. Right-handedness. 5. Han Chinese. 6. Signed a written informed consent, willing to participate in the study and be evaluated. Exclusion Criteria: 1. Co-morbid other mental disorders, including: schizophrenia, mental retardation, substance dependence, etc. 2. Patients with metal objects in the body or with other contraindications to MRI scanning 3. Patients with severe or unstable somatic diseases 4. Women during pregnancy or lactation, and women of childbearing age with positive urine HCG test results during the screening period 5. Other conditions that, in the opinion of the investigator, exist that make participation in this clinical trial inappropriate.

Contact & Investigator

Central Contact

Manli Huang, M.D

✉ huangmanli@zju.edu.cn

📞 13957162975

Frequently Asked Questions

Who can join the NCT05607654 clinical trial?

This trial is open to participants of all sexes, aged 18 Years or older, up to 45 Years, studying Treatment-resistant Depression. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT05607654 currently recruiting?

Yes, NCT05607654 is actively recruiting participants. Contact the research team at huangmanli@zju.edu.cn for enrollment information.

Where is the NCT05607654 trial being conducted?

This trial is being conducted at Hangzhou, China.

Who is sponsoring the NCT05607654 clinical trial?

NCT05607654 is sponsored by First Affiliated Hospital of Zhejiang University. The trial plans to enroll 60 participants.

Related Trials

Related Intelligence Guides

In-depth guides covering this condition's trials, eligibility, and what to expect.

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: July 2026  ·  Data Methodology